MTOR and renal cell carcinoma: In this regard, the available treatments for RCC are a combining targeted therapy that includes anti-angiogenic agents (tyrosine kinase inhibitors, such as sorafenib, sunitinib, pazopanib, and axitinib), or an anti-angiogenic antibody routinely employed in combination with interferon alpha (bevacizumab) [7, 8], and antiproliferative agents (mTOR inhibitors, such as temsirolimus and everolimus) [9].